Researchers from Carnegie Mellon University have developed a novel way of labeling stem cells. Mesenchymal Stem Cells (MSCs) were engineered to uptake an iron-oxide nanoparticle called Ferumoxytol, which is picked up by means of magnetic resonance imaging (MRI). These developments allow researchers to assess cell migration and integration with a variety of tissues, aiding in clinical investigation of stem cell therapies.
Ferumoxytol is currently the only FDA approved nanoparticle for human use. Previous attempts to incorporate the biolabel have relied on transfection agents, which drastically change the cells’ biology and effectiveness. The new labeling procedure emulated in-vivo environments, introducing other cells from the bone marrow onto expanded stem cells. Resultant MSCs retain optimal size and regenerative capabilities, while internalizing Ferumoxytol for cell tracking. Through this protocol, scientists are able to deduce the mechanisms of regenerative medicine.
As regenerative engineering progresses, we believe the best stem cells to use in emerging treatments will be the patient’s own [autologous stem cells] as this negates the need to find a suitable donor and eliminates the chances of rejection of the transplanted tissue. To learn more about banking your own valuable stem cells to insure your family’s future health, visit StemSave or call 877-783- 6728 (877-StemSave) today.
The Future of Regenerative Medicine is Now™
To view the full article, click here.
